Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma ...Middle East

Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX FASPRO® combination biweekly regimen showed an overall response rate of more than 80 percent CHICAGO, June 3, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson...

Hence then, the article about janssen presents longer term talquetamab follow up data showing overall response rates of more than 70 percent in heavily pretreated patients with multiple myeloma was published today ( Saturday 03/06/2023 - 10:41 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma )

Also on site :

• Saudi Arabia to unify LPG gas cylinder prices nationwide from January 2026
• Two dozen killed in Ukrainian strike on Russian New Year’s celebration – governor
• Volunteer in Iran’s Revolutionary Guard reportedly killed during widening protests